The Hyderabad based Suven Life Sciences has set-up a Scientific Advisory Board (SAB) for Drug Discovery Research consisting of three well known specialists namely Dr. Marlene L. Cohen, Dr. James L. Howard and Dr. Warren Stern, in the therapeutic area of Central Nervous System (CNS) in which Suven is heavily involved.

SAB serves as a think tank by providing right inputs, direction and guidance to the Suven's management and to it’s scientific team for all of it’s pursuits in the Drug Discovery Research.

At the first Scientific Advisory Board meeting held at Suven Life Sciences LLC, USA, SAB adjudged Suven Life Sciences as well positioned and in the right direction in its chosen field of Drug Discovery Research (CNS) on the basis of work already done and the facilities created by Suven. It was proposed to have these SAB meetings thrice every year.

Dr. Marlene L. Cohen had worked for Eli Lilly and Company, Indianapolis, USA, for more than 27 years and holds the prestigious title Lilly Research Fellow. She has served at different capacities in various professional organisations including ASPET, FASEB. She is also an adjunct professor of the Indiana University School of Medicine and currently she is consultant, Creative Pharmacology Solutions LLC. She has been involved all through her career in the discovery and development of many serotonergic compounds for CNS therapeutic area. She obtained her Ph.D in 1973 from University of California, San Francisco Medical Center, USA, and post-doctoral fellow from Roche Institute of Molecular Biology, Nutley, NJ, USA.

Dr. James L. Howard had worked for several years at University of North Carolina (6 years) and Burroughs Wellcome Company (20 years), USA and currently he is a senior partner, Howard Associates LLC. He served at different capacities in various professional organisations including American Psychological Society, Society of Neurosciences, Behavioural Pharmacology Society. He brings rich experience of behavioural pharmacology and experimental methods to evaluate potential candidates to develop drugs for CNS therapeutic area. Dr. Howard obtained his Ph.D. in 1968 from Tulane University, USA.

Dr. Warren Stern, Ph.D. is senior vice president, Drug Development of DOV Pharmaceutical, Inc. since 2003. Prior to joining DOV, he served as senior vice president of Scientific and Medical Services at Parexel International Corporation, a major contract research organization, where he has worked for the past five and one-half years. He has also held senior level positions in clinical research at Cato Research Ltd., a CRO, Forest Laboratories, Inc. and earlier, Burroughs Wellcome Co. Previously, he was president and CEO of Pharmatec Inc., a CNS-oriented drug delivery company. He has also founded two drug delivery companies, Research Triangle Pharmaceuticals and Nobex, Inc. Dr. Stern has over 25 years' experience in drug development in CNS and other fields. He directed the successful NDA submissions of bupropion (Wellbutrin) and citalopram (Celexa). He is the inventor on six patents, including patents related to CNS products, and two drug delivery systems. He received his Ph.D. in psychopharmacology from Indiana University in 1969 and completed postdoctoral fellowships at Boston State Hospital and at the Worcester Foundation for Experimental Biology.